A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)-MedSci.cn

A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)

Harding, JJ; Abou-Alfa, GK; Shi, YK; Whang-Peng, J; Yuen, MF; Saif, WM; Tian, AP; Gu, SZ; Lam, W; Liu, SH; Cheng, YC; Chu, E; Yen, Y

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (4):

科室
- - 订阅+
  - 更多科室
工具
服务